Immunix
Precision medicine platform powering the world's largest biobank for infection in acute care
Platform · HybridCompany source
Company profile
About Prenosis
Prenosis is a biology-based technology company that develops precision medicine tools for critical acute care conditions. The company's mission is to empower clinicians to see patients differently by providing deep understanding of each patient's unique biology, enabling tailored treatments and improved outcomes. Prenosis leverages its Immunix precision medicine platform, which has created the world's largest biomarker-clinical dataset for infection in acute care, to develop and validate new diagnostic tools. The company's flagship product, the Sepsis ImmunoScore, is the first FDA-authorized AI diagnostic for sepsis. By integrating biomarkers and clinical data through machine learning, the Sepsis ImmunoScore evaluates a patient's risk of experiencing adverse outcomes within 24 hours. The diagnostic seamlessly integrates into hospital Electronic Health Records, enabling timely interventions that improve patient outcomes, enhance hospital quality metrics, and reduce costs. Prenosis serves health systems and hospitals, with direct EMR integration and an exclusive partnership with Roche Diagnostics for broader distribution. The company's Immunix platform simultaneously enables the development of new precision medicine tools while implementing them in real-time to improve patient care.
Company description Prenosis official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Prenosis?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Critical acute care conditions
- Sepsis
- Serious infections
Who it serves
- Health Systems
- Hospitals
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Recorded integration context: Electronic Health Records, Electronic Medical Records.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Bobby Reddy Jr. named to TIME's 2025 TIME100 Health List (May 2025). Sepsis ImmunoScore named TIME Best Invention of 2024 (October 2024). New England Journal of Medicine study published (December 2024). FDA De Novo Authorization received for Sepsis ImmunoScore.
Partnerships
Recorded partners
- Roche Diagnostics
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Sepsis ImmunoScore
First FDA-authorized AI diagnostic for sepsis detection and prediction of adverse outcomes
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Interpretability of an FDA-authorized AI/ML sepsis diagnostic tool improved by SHAP values.JAMIA open · Feb 1, 2026
Multivariate protein landscape of host response in hospitalised patients with suspected infection in the emergency department.Nature communications · Aug 22, 2025
Distinct immune profiles and clinical outcomes in sepsis subphenotypes based on temperature trajectories.Intensive care medicine · Dec 1, 2024
Analysis of Protein Biomarkers From Hospitalized COVID-19 Patients Reveals Severity-Specific Signatures and Two Distinct Latent Profiles With Differential Responses to Corticosteroids.Critical care medicine · Dec 1, 2023
Diagnostic and prognostic capabilities of a biomarker and EMR-based machine learning algorithm for sepsis.Clinical and translational science · Jul 1, 2021
Publisher Correction: Combining Biomarkers with EMR Data to Identify Patients in Different Phases of Sepsis.Scientific reports · Nov 19, 2019
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Sepsis ImmunoScoreDEN230036 · De Novo · Apr 2, 2024
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Improved patient outcomes
Through timely interventions enabled by early sepsis detection
Improved hospital quality metrics
Via Sepsis ImmunoScore implementation
Reduced hospital costs
Through optimized sepsis care delivery
New England Journal of Medicine Study
Validation of Sepsis ImmunoScore diagnostic and predictive power for sepsis
Study concluded that the Sepsis ImmunoScore has both significant diagnostic and predictive power
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Bobby Reddy, Jr.
CEO
Vanessa Rollings Giannis
Senior Advisor, PACE Healthcare Capital
Meghann Howland
SVP, Global Clinical Research Operations
Avinash Sastry
VP of Engineering
William Harty
VP of Integration Services
Jim Sianis
Executive Director of Business Development
Mark Wagner
Serial Medtech Operator
Nam Nguyen
Informatics Executive Consultant
06 · Company updates
Updates from Prenosis
Recent articles published on Prenosis's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.